Pathology & Oncology Research

, Volume 16, Issue 2, pp 143–148

Panitumumab: An Arrow on Target


DOI: 10.1007/s12253-010-9257-7

Cite this article as:
Kopper, L. Pathol. Oncol. Res. (2010) 16: 143. doi:10.1007/s12253-010-9257-7


Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what is well-tolerated, effective as a single agent in chemotherapy refractory patients and in different combinations. The clinical response is restricted to tumors with wild-type RAS, therefore the RAS status should be checked before treatment.


PanitumumabColorectal cancerAnti-EGFR therapy

Copyright information

© Arányi Lajos Foundation 2010

Authors and Affiliations

  1. 1.Ist Department of Pathology and Experimental Cancer ResearchSemmelweis UniversityBudapestHungary